TrialHuman vaccines & immunotherapeutics2023

Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial.

Guang-Wei Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.